On most occasions, the reported tumor types matched the patient’s genetic findings, e.g. early-onset breast (family history of patients with findings in BRCA1, BRCA2, BRIP1, NF1), prostate (BRCA2, FANCM, TP53, WT1), renal (TSC1), gynecological (BRIP1, TSC1), and hematological cancers (MLH1, TP53, WT1). This evidence concerns the gene BRCA1 and hematopoietic and lymphoid cell neoplasm.